Nalbuphine
(YZLZPSJXMWGIFH-BCXQGASESA-N)
Structure
- SMILES
- O[C@H]1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CCC2)ccc1O)O.Cl
- Molecular Formula:
- C21H28ClNO4
- Molecular Weight:
- 393.904
- Log P:
- 2.4472
- Hydrogen Bond Acceptor:
- 5
- Hydrogen Bond Donor:
- 4
- TPSA:
- 73.16
- CAS Number(s):
- 23277-43-2; 59052-16-3
Synonym(s)
1.
Nalbuphine
2.
EN-2234A
3.
Nalbuphine Hydrochloride
4.
Nalbuphine Serb
5.
Nubain
6.
EN 2234A
7.
EN2234A
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug abuser | FAERS: 9 | US FAERS | |
| 2 | Nausea | FAERS: 7 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 3 | Vomiting | FAERS: 7 | US FAERS | |
| 4 | Headache | FAERS: 6 | US FAERS | |
| 5 | Tremor | FAERS: 5 | US FAERS | |
| 6 | Asthenia | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 7 | Burning sensation | FAERS: 4 | US FAERS | |
| 8 | Dizziness | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 9 | Drug Dependence | FAERS: 4 | US FAERS | |
| 10 | Pain | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 11 | Pruritus | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 12 | Agitation | FAERS: 3 | US FAERS | |
| 13 | Anxiety | FAERS: 3 | US FAERS | |
| 14 | Chest discomfort | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 15 | Drug exposure during pregnancy | FAERS: 3 | US FAERS | |
| 16 | Drug withdrawal syndrome | FAERS: 3 | US FAERS | |
| 17 | Incoherent | FAERS: 3 | US FAERS | |
| 18 | Restlessness | FAERS: 3 | US FAERS | |
| 19 | Apparent death | FAERS: 2 | US FAERS | |
| 20 | Cyanosis | FAERS: 2 | US FAERS | |
| 21 | Depressed Level of Consciousness | FAERS: 2 | US FAERS | |
| 22 | Electrocardiogram abnormal | FAERS: 2 | US FAERS | |
| 23 | Formication | FAERS: 2 | US FAERS | |
| 24 | Hypersensitivity | FAERS: 2 | US FAERS | |
| 25 | Lethargy | FAERS: 2 | US FAERS | |
| 26 | Muscle Rigidity | FAERS: 2 | US FAERS | |
| 27 | Myalgia | FAERS: 2 | US FAERS | |
| 28 | Overdose | FAERS: 2 | US FAERS | |
| 29 | Post-Traumatic Stress Disorder | FAERS: 2 | US FAERS | |
| 30 | Screaming | FAERS: 2 | US FAERS | |
| 31 | Swelling | FAERS: 2 | US FAERS | |
| 32 | Tachycardia | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 33 | Abdominal Pain | FAERS: 1 | US FAERS | |
| 34 | Altered state of consciousness | FAERS: 1 | US FAERS | |
| 35 | Amnesia | FAERS: 1 | US FAERS | |
| 36 | Anaphylactic shock | FAERS: 1 | US FAERS | |
| 37 | Aphasia | FAERS: 1 | US FAERS | |
| 38 | Arthralgia | FAERS: 1 | US FAERS | |
| 39 | Arthritis | FAERS: 1 | US FAERS | |
| 40 | Cerebral Palsy | FAERS: 1 | US FAERS | |
| 41 | Chest Pain | FAERS: 1 | US FAERS | |
| 42 | Chills | FAERS: 1 | US FAERS | |
| 43 | Congenital brain damage | FAERS: 1 | US FAERS | |
| 44 | Delirium | FAERS: 1 | US FAERS | |
| 45 | Documented hypersensitivity to administered product | FAERS: 1 | US FAERS | |
| 46 | Drug ineffective for unapproved indication | FAERS: 1 | US FAERS | |
| 47 | Drug screen false positive | FAERS: 1 | US FAERS | |
| 48 | Drug screen positive | FAERS: 1 | US FAERS | |
| 49 | Dysarthria | FAERS: 1 | US FAERS | |
| 50 | Fatigue | FAERS: 1 | US FAERS | |
| 51 | Feeding disorder neonatal | FAERS: 1 | US FAERS | |
| 52 | Feeling Cold | FAERS: 1 | US FAERS | |
| 53 | Feeling jittery | FAERS: 1 | US FAERS | |
| 54 | Forceps delivery | FAERS: 1 | US FAERS | |
| 55 | Gout | FAERS: 1 | US FAERS | |
| 56 | Hemiplegia | FAERS: 1 | US FAERS | |
| 57 | Hostility | FAERS: 1 | US FAERS | |
| 58 | Hyperacusis | FAERS: 1 | US FAERS | |
| 59 | Hysterectomy | FAERS: 1 | US FAERS | |
| 60 | Injection related reaction | FAERS: 1 | US FAERS | |
| 61 | Maternal exposure during pregnancy | FAERS: 1 | US FAERS | |
| 62 | Memory impairment | FAERS: 1 | US FAERS | |
| 63 | Mental impairment | FAERS: 1 | US FAERS | |
| 64 | Mental status changes | FAERS: 1 | US FAERS | |
| 65 | Metabolic acidosis | FAERS: 1 | US FAERS | |
| 66 | Muscle tightness | FAERS: 1 | US FAERS | |
| 67 | Myocardial Infarction | FAERS: 1 | US FAERS | |
| 68 | Myoclonus | FAERS: 1 | US FAERS | |
| 69 | Neonatal disorder | FAERS: 1 | US FAERS | |
| 70 | Neonatal respiratory arrest | FAERS: 1 | US FAERS | |
| 71 | Neonatal respiratory depression | FAERS: 1 | US FAERS | |
| 72 | Pallor | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 73 | Palpitations | FAERS: 1 | US FAERS | |
| 74 | Pancreatitis | FAERS: 1 | US FAERS | |
| 75 | Patient restraint | FAERS: 1 | US FAERS | |
| 76 | Peripartum cardiomyopathy | FAERS: 1 | US FAERS | |
| 77 | Physical product label issue | FAERS: 1 | US FAERS | |
| 78 | Presyncope | FAERS: 1 | US FAERS | |
| 79 | Product administration error | FAERS: 1 | US FAERS | |
| 80 | Product quality issue | FAERS: 1 | US FAERS | |
| 81 | Product storage error | FAERS: 1 | US FAERS | |
| 82 | Retching | FAERS: 1 | US FAERS | |
| 83 | Sinus Tachycardia | FAERS: 1 | US FAERS | |
| 84 | Stillbirth | FAERS: 1 | US FAERS | |
| 85 | Therapy non-responder | FAERS: 1 | US FAERS | |
| 86 | Thirst | FAERS: 1 | US FAERS | |
| 87 | Tinnitus | FAERS: 1 | US FAERS | |
| 88 | Traumatic Brain Injury | FAERS: 1 | US FAERS | |
| 89 | Unevaluable event | FAERS: 1 | US FAERS | |
| 90 | Unresponsive to stimuli | FAERS: 1 | US FAERS | |
| 91 | Unresponsive to verbal stimuli | FAERS: 1 | US FAERS | |
| 92 | Visual Impairment | FAERS: 1 | US FAERS | |
| 93 | nervous system disorder | FAERS: 1 | US FAERS | |
| 94 | Akathisia | Canada Vigilance: 1 | Canada Vigilance | |
| 95 | Anaphylactoid Reaction | Canada Vigilance: 1 | Canada Vigilance | |
| 96 | Dysgeusia | Canada Vigilance: 1 | Canada Vigilance | |
| 97 | Flushing | Canada Vigilance: 2 | Canada Vigilance | |
| 98 | Hypotension | Canada Vigilance: 1 | Canada Vigilance | |
| 99 | Respiratory Depression | Canada Vigilance: 1 | Canada Vigilance | |
| 100 | Sudden death | Canada Vigilance: 1 | Canada Vigilance | |
| 101 | Syncope | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.